NovoCure Surpasses Q1 Expectations

NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s estimate of $146 million. GAAP earnings per share (EPS) were a negative $0.31, beating expectations of a negative $0.46 per share. The quarter was marked by robust patient growth and progress in clinical trials, though challenges in gross margins remain.Source: Analyst estimates for the quarter provided by FactSet.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool